Ying Yuan, Ph.D.

2005 University of Michigan, Ann Arbor, Ann Arbor, MI 
Biostatistics Biology
"Ying Yuan"


Sign in to add mentor
Roderick Joseph Alexander Little grad student 2005 University of Michigan
 (Model-based estimates of the finite population mean for two -stage cluster samples with nonresponse.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Yuan Y, Zhou H, Liu S. (2024) Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical Trials (London, England). 17407745231207085
Zhao Y, Yuan Y, Korn EL, et al. (2023) Backfilling Patients in Phase I Dose Escalation Trials Using Bayesian Optimal Interval Design (BOIN). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Zhang W, Laird G, Chen J, et al. (2023) A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints. Statistics in Medicine
Thall PF, Zang Y, Chapple AG, et al. (2023) Novel clinical trial designs with dose optimization to improve long-term outcomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Lin R, Shi H, Yin G, et al. (2022) BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS. The Annals of Applied Statistics. 16: 2481-2504
Zhou Y, Lin R, Lee JJ, et al. (2022) TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Statistics in Medicine
Lin R, Thall PF, Yuan Y. (2021) A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Analysis. 16: 179-202
Jiang L, Li R, Yan F, et al. (2021) Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemporary Clinical Trials. 106338
Shi H, Cao J, Yuan Y, et al. (2021) uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials. Statistics in Medicine
Atkins JT, George GC, Hess K, et al. (2020) Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. British Journal of Cancer
See more...